Get the Stockscreener App
64.12
1.07%
0.68
Belite Bio Inc Adr Stock (BLTE) Forecast
The Belite Bio Inc Adr (BLTE) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $67.59, representing a +5.41% increase from the current price of $64.12. The highest analyst price target is $70.06, and the lowest is $65.13.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month BLTE Price Target
Average 71.85
(+12.05% Upside)
Is Belite Bio Inc Adr (BLTE) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 44.50 | Neutral |
| STOCH(9,6) | 23.90 | Neutral |
| STOCHRSI(14) | 27.11 | Neutral |
| MACD(12,26) | -2.0985 | Sell |
| ADX(14) | 17.91 | Neutral |
| William %R | -75.58 | Neutral |
| CCI(14) | -15.05 | Neutral |
Buy: 0
Sell: 1
Neutral: 6
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
63.69
Buy
|
64.36
Sell
|
| MA20 |
66.13
Sell
|
66.36
Sell
|
| MA50 |
68.63
Sell
|
65.87
Sell
|
| MA100 |
58.81
Buy
|
61.09
Buy
|
| MA200 |
51.51
Buy
|
54.46
Buy
|
Buy: 5
Sell: 5
Neutral: 0
Summary: Neutral
According to our latest analysis, BLTE could be considered a Neutral, with 17 technical analysis indicators signaling 5 Buy signals, 6 signaling Sell signals and 6 Neutral signals. This suggests that investors should exercise caution when entering new positions on BLTE, as the market is likely to remain volatile in the near term.
- RSI (Relative Strength Index): The RSI(14) value of 44.5 indicates that BLTE is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 23.9 indicates that BLTE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 27.11 indicates that BLTE is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 17.91 indicates that there is no clear directional movement, and the market may be ranging or moving sideways.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -15.05 indicates that BLTE is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term BLTE price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Belite Bio Inc Adr financial reports and earnings history, Belite Bio Inc Adr (BLTE) stock could reach $160.85 by 2030, $442.79 by 2040 and $421.03 by 2050. See the projected annual prices until 2050 of the Belite Bio Inc Adr stock below:
- Belite Bio Inc Adr (BLTE) is expected to reach an average price of $283.06 in 2035, with a high prediction of $286.92 and a low estimate of $265.50. This indicates an $341.45% rise from the last recorded price of $64.12.
- Belite Bio Inc Adr (BLTE) stock is projected to chart a bullish course in 2040, with an average price target of $442.53, representing an $590.16% surge from its current level. The forecast ranges from a conservative $432.79 to a sky-high $442.79.
- Our analysts predict Belite Bio Inc Adr (BLTE) to jump 313.98% by 2045, soaring from $258.11 to an average price of $265.44, potentially reaching $605.64. While $258.11 is the low estimate, the potential upside is significant.
- Belite Bio Inc Adr (BLTE) stock is expected to climb by 2050, reaching an average of $421.03, a $556.62% jump from its current level. However, a wide range of estimates exists, with high and low targets of $421.03 and $395.32, respectively, highlighting the market's uncertainty.
Belite Bio Inc Adr Stock (BLTE) Year by Year Forecast
Belite Bio Inc Adr Stock (BLTE) Price Forecast for 2025
Belite Bio Inc Adr Stock (BLTE) is expected to reach an average price of $71.85 in 2025, with a high prediction of $86.52 and a low estimate of $57.17. This indicates an +12.05% rise from the last recorded price of $64.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $67.83 | $65.13 | $70.06 | +5.79% |
| February, 2025 | $67.81 | $64.62 | $69.34 | +5.75% |
| March, 2025 | $70.49 | $67.75 | $70.53 | +9.93% |
| April, 2025 | $73.18 | $70.81 | $74.58 | +14.13% |
| May, 2025 | $70.99 | $67.27 | $73.70 | +10.72% |
| June, 2025 | $71.83 | $69.91 | $74.87 | +12.02% |
| July, 2025 | $62.37 | $59.12 | $72.17 | -2.73% |
| August, 2025 | $60.78 | $57.17 | $62.98 | -5.21% |
| September, 2025 | $71.86 | $59.42 | $72.26 | +12.08% |
| October, 2025 | $83.18 | $69.06 | $83.35 | +29.73% |
| November, 2025 | $82.83 | $76.96 | $86.37 | +29.18% |
| December, 2025 | $86.46 | $79.95 | $86.52 | +34.84% |
Belite Bio Inc Adr Stock (BLTE) Price Forecast for 2026
The predicted value for Belite Bio Inc Adr (BLTE) in 2026 is set at an average of $83.28. Estimates vary from a peak of $107.25 to a trough of $59.31, indicating an +29.88% surge from the present price of $64.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $92.83 | $85.26 | $94.09 | +44.78% |
| February, 2026 | $96.89 | $89.72 | $97.27 | +51.10% |
| March, 2026 | $101.79 | $95.49 | $102.74 | +58.75% |
| April, 2026 | $101.06 | $94.66 | $103.91 | +57.61% |
| May, 2026 | $105.59 | $100.96 | $107.18 | +64.68% |
| June, 2026 | $98.65 | $94.36 | $107.25 | +53.84% |
| July, 2026 | $95.20 | $92.77 | $105.34 | +48.47% |
| August, 2026 | $65.87 | $59.31 | $103.87 | +2.73% |
| September, 2026 | $67.83 | $62.93 | $68.08 | +5.79% |
| October, 2026 | $86.57 | $68.68 | $90.63 | +35.01% |
| November, 2026 | $97.73 | $86.97 | $102.60 | +52.42% |
| December, 2026 | $86.73 | $82.52 | $99.81 | +35.26% |
Belite Bio Inc Adr Stock (BLTE) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Belite Bio Inc Adr (BLTE) is $102.11, with a high forecast of $117.86 and a low forecast of $86.35. This indicates an +59.24% increase from the last price of $64.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $102.51 | $86.35 | $102.51 | +59.88% |
| February, 2027 | $94.02 | $91.65 | $104.19 | +46.63% |
| March, 2027 | $94.51 | $93.93 | $99.11 | +47.40% |
| April, 2027 | $105.30 | $94.82 | $105.47 | +64.22% |
| May, 2027 | $104.67 | $101.75 | $106.36 | +63.24% |
| June, 2027 | $107.60 | $102.52 | $109.07 | +67.80% |
| July, 2027 | $112.09 | $107.49 | $114.15 | +74.82% |
| August, 2027 | $111.27 | $111.27 | $115.66 | +73.53% |
| September, 2027 | $116.18 | $108.98 | $117.86 | +81.19% |
| October, 2027 | $111.55 | $110.43 | $116.78 | +73.97% |
| November, 2027 | $105.97 | $104.02 | $114.53 | +65.27% |
| December, 2027 | $107.69 | $103.34 | $109.47 | +67.96% |
Belite Bio Inc Adr Stock (BLTE) Price Forecast for 2028
In 2028, Belite Bio Inc Adr (BLTE) is projected to reach an average price of $125.63, with a high projection of $167.10 and a low estimate of $84.16. This indicates an +95.93% rise from the last price of $64.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $121.05 | $108.44 | $121.05 | +88.79% |
| February, 2028 | $133.70 | $118.39 | $136.05 | +108.51% |
| March, 2028 | $134.38 | $127.27 | $135.99 | +109.57% |
| April, 2028 | $142.32 | $132.17 | $143.67 | +121.97% |
| May, 2028 | $145.97 | $141.31 | $147.58 | +127.65% |
| June, 2028 | $155.63 | $145.16 | $156.04 | +142.72% |
| July, 2028 | $159.16 | $151.01 | $159.42 | +148.22% |
| August, 2028 | $164.08 | $157.09 | $164.08 | +155.90% |
| September, 2028 | $165.60 | $162.44 | $165.78 | +158.26% |
| October, 2028 | $159.99 | $154.53 | $167.10 | +149.52% |
| November, 2028 | $165.41 | $154.54 | $165.79 | +157.96% |
| December, 2028 | $89.14 | $84.16 | $166.59 | +39.02% |
Belite Bio Inc Adr Stock (BLTE) Price Forecast for 2029
The 2029 price forecast for Belite Bio Inc Adr Stock (BLTE) is $123.50 on average, with a high prediction of $156.74 and a low estimate of $90.26. This represents an +92.61% increase from the previous price of $64.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $110.21 | $90.26 | $111.96 | +71.89% |
| February, 2029 | $128.03 | $108.77 | $129.75 | +99.68% |
| March, 2029 | $119.24 | $115.96 | $131.59 | +85.97% |
| April, 2029 | $124.80 | $112.78 | $125.49 | +94.64% |
| May, 2029 | $131.01 | $124.16 | $136.36 | +104.33% |
| June, 2029 | $130.06 | $124.46 | $133.27 | +102.84% |
| July, 2029 | $132.10 | $128.65 | $133.51 | +106.02% |
| August, 2029 | $140.23 | $133.56 | $142.67 | +118.69% |
| September, 2029 | $142.19 | $139.43 | $144.16 | +121.76% |
| October, 2029 | $149.47 | $143.65 | $149.47 | +133.11% |
| November, 2029 | $154.48 | $150.42 | $155.70 | +140.92% |
| December, 2029 | $156.01 | $150.70 | $156.74 | +143.30% |
Belite Bio Inc Adr Stock (BLTE) Price Forecast for 2030
Belite Bio Inc Adr Stock (BLTE) is expected to reach an average price of $186.64 in 2030, with a high forecast of $224.35 and a low forecast of $148.92. This signifies an +191.07% surge from the last price of $64.12.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $159.08 | $155.26 | $160.85 | +148.10% |
| February, 2030 | $151.19 | $148.92 | $160.06 | +135.79% |
| March, 2030 | $149.70 | $149.52 | $154.15 | +133.46% |
| April, 2030 | $159.81 | $150.97 | $160.84 | +149.23% |
| May, 2030 | $178.41 | $160.69 | $178.91 | +178.24% |
| June, 2030 | $182.44 | $175.59 | $186.30 | +184.53% |
| July, 2030 | $187.70 | $181.52 | $188.03 | +192.74% |
| August, 2030 | $198.55 | $186.87 | $199.32 | +209.66% |
| September, 2030 | $205.41 | $195.49 | $205.62 | +220.35% |
| October, 2030 | $213.86 | $204.34 | $214.81 | +233.54% |
| November, 2030 | $217.53 | $207.37 | $218.53 | +239.26% |
| December, 2030 | $223.36 | $214.72 | $224.35 | +248.35% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):